[go: up one dir, main page]

WO2011000396A1 - Purification of letrozole intermediate - Google Patents

Purification of letrozole intermediate Download PDF

Info

Publication number
WO2011000396A1
WO2011000396A1 PCT/EP2009/004959 EP2009004959W WO2011000396A1 WO 2011000396 A1 WO2011000396 A1 WO 2011000396A1 EP 2009004959 W EP2009004959 W EP 2009004959W WO 2011000396 A1 WO2011000396 A1 WO 2011000396A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
letrozole
process according
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/004959
Other languages
French (fr)
Inventor
Rudolf Smrz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Priority to PCT/EP2009/004959 priority Critical patent/WO2011000396A1/en
Publication of WO2011000396A1 publication Critical patent/WO2011000396A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Definitions

  • Letrozole is indicated for, inter alia, treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. It is a non-steroidal competitive inhibitor of the aromatase enzyme system. Letrozole is marketed under the brand name FEMARA ® by Novartis Pharmaceuticals as a film coated tablet containing 2.5 mg of letrozole as the free base.
  • US 5,280,035 describes a process for making compound (IV) by converting 1 ,2,4-triazole into sodium salt ( by sodium hydride in DMF), followed by the reaction of this salt with (II).
  • the compound (IV) must still be purified by column chromatography for to obtain the desired purity.
  • US appl. 2005/0209294 isolates the compound (IV) by extraction/crystallization, however allowing for obtaining the product only with 96% purity.
  • WO 2007- 100346 improves the reaction between the 1 ,2,4-triazole salt and
  • WO 2007- 107733 discloses a process of making the compound (IV) employing the reaction of (II) and (III) in a presence of cesium carbonate. Under such process, the amounts of the formed undesired isomer (IVa) are lower.
  • WO 2005-047269 provides a crystallization process for purification of the mixtures of compounds (IV) and (IVa) comprising dissolving the isomeric mixture in dichloromethane, adding an isopropanolic solution of hydrogen chloride thereto, and adding isopropyl ether to the mixture to precipitate the undesired isomer ( i.e. the compound (IVa) ) in its hydrochloride form.
  • the desired compound (IV) is then obtained from the filtrate by the precipitation as the hydrochloride salt and is then converted into a base.
  • WO 2007-100346 suggests a purification process based on an extraction involving an aqueous phase and water immiscible phase, which preferably contains C5-C12 hydrocarbon such as toluene, benzene and hexane.
  • an aqueous phase and water immiscible phase which preferably contains C5-C12 hydrocarbon such as toluene, benzene and hexane.
  • the content of the iso-product (IVa) may be decreased to 1.5 %. This process is more effective than the extraction /crystallization process of US appl. 2005/0209294 shown above.
  • the raw intermediate (IV) may be further purified as its acid salt, e.g., the hydrochloride, hydrobromide or methane sulfonate.
  • the raw intermediate (IV) is dissolved in acetone, and the hydrochloride of (IV) is precipitated by adding concentrated aqueous HCl to this acetonic solution.
  • the hydrochloride of the iso-product (IVa) remains in the solution.
  • a first aspect of the invention provides a process for purification of 4-[l-(l,2,4-triazolyl)methyl]benzonitrile of the formula (IV), comprising contacting the material comprising the compound (IV) and impurities, reaction side products and starting materials, such as the compound (IVa), with an aqueous acid, preferably hydrochloric acid, and precipitating the solid state compound (IV) from the mixture.
  • This precipitation comprises preferably adjusting the pH to less acidic value.
  • the aqueous acid is preferably diluted hydrochloric acid , which preferably has a concentration of between 5 to 20 % ( w/v).
  • 1 weight part of the material comprising the compound (IV) admixed with / impurified by the compound (IVa) is contacted with 2.5- 10 volume parts of the aqueous solution of the acid, preferably the hydrochloric acid.
  • the relative molar amount of the acid in respect to the molar amount of the compound (IV) is 1.5:1 to 2.5 :1.
  • the pH at the precipitation is adjusted to a value of at least 3.0 , preferably between 3.0 - 1 1.0, more preferably 6 - 10.
  • the invention relates to a process for making a pharmaceutical grade letrozole of the formula (I) comprising the steps of
  • the present invention can purify the letrozole intermediate of the formula (IV) without the need to convert crude compound (IV) into an isolated acid addition salt thereof and/or to employ extraction steps using organic solvents.
  • a simple process comprising precipitation of the compound (IV) as a free base from a solution thereof in a diluted aqueous acid may be employed, whereby the process allows to decrease not only the content of the iso- impurity of formula (IVa) but also other impurities arisen from the synthesis.
  • a reagent grade compound of the formula (IV) i.e.
  • the purification process of the present invention is based on the finding that compounds (IV) and (IVa) have different solubility in the solvent comprising the diluted aqueous acid, particularly diluted aqueous hydrochloric acid , at different values of pH.
  • a mixture of compounds (IV) and (IVa) which typically arises from the synthesis comprising a condensation of the compound (II) and (III) and isolation of the reaction product from the reaction mixture, is dissolved in a diluted aqueous acid, particularly hydrochloric acid, and the pH of the mixture is adjusted to a less acidic value, typically to a pH higher than 3.0, the compound (IV) preferably precipitates from the solution as a free base, while the compound (IVa) stays dissolved in the solvent.
  • a diluted aqueous acid particularly hydrochloric acid
  • the first step of the purification process comprises contacting the crude compound (IV), i.e. the material comprising an admixture of the compound (IV) with the compound (IVa), herein referred to as the material , with a diluted aqueous acid.
  • the crude material is typically obtained by a synthesis comprising a condensation of the compound (II) and (III), the conditions of which are well known in the art, eventually followed by pre- purification steps. In general, more than 0.5 %, sometimes even up to 5-10 %, of the iso- impurity (IVa) may be present in the material.
  • the material may also comprise other impurities arising from the synthesis, particularly the unreacted 1,2,4-triazol and colour- forming impurities.
  • the amount of the compound of formula (IV) in the starting material may be determined by routine analytical methods, e.g. by HPLC.
  • the amount of the acid in the diluted aqueous acid is usually from 0.1 to 3 molar equivalents, more typically 1.5 to 2.5 molar equivalents, in respect to the compound of formula (IV).
  • concentration the acid is normally less than 20%, preferably between 5 and 20%, based on the amount of water present.
  • volume the amount of the diluted aqueous acid is typically within the range of 2.5- 10 volume parts per 1 weight part of the crude material to be purified.
  • the preferred acid is hydrochloric acid.
  • hydrochloric acid is only an example of a suitable acid useful in the inventive process and the invention is by no way limited to using this acid only.
  • the mixture of the material and diluted aqueous acid is preferably heated to an enhanced temperature , preferably at a temperature of between 30 and 60 C and allowed to stir for certain time.
  • the formed mixture is filtered to remove the solids and to form a clear filtrate.
  • the solids are particularly represented by structurally related impurities present in the material.
  • a small amount of a surface active material such as activate carbon or kieselguhr is added prior to the filtration to the mixture , which not only enhances the speed of the filtration, but adsorbs also other impurities present in the starting material.
  • the compound (IV) purified by the above process is useful in a process for making letrozole. Accordingly, the above purification process steps may be followed by a subsequent step of converting the purified compound (IV) to letrozole, particularly by a condensation with the 4-fIuorobenzonitrile of the formula (V).
  • the conditions of the condensation as well as of the isolation of letrozole from the reaction mixture are known in the art.
  • the letrozole may be produced with a low content of the isoletrozole of the formula (Ia), which is desirable from the pharmaceutical perspective.
  • a pharmaceutical grade letrozole i.e. a product having the content of the title compound of at least 99.7% and the content of any single structurally related impurity of less than 0.1 %, may be obtained in a simple and reliable process on an industrial scale.
  • the mother liquors were alkalinized by 2M aqueous NaOH at 10-15 °C to pH 8.0, 2 g of NaCl were added and the mixture was stirred at ambient temperature for 0.5 hours. Allowed to stand overnight at 5-7 °C. The solid was filtered and dried at an ambient temperature to constant mass ( 2nd crop).
  • the mother liquors were mixed with 2.2 g of NaCl and the mixture was stirred at ambient temperature for 0.5 hours. Allowed to stand overnight at 5-7 °C. The solid was filtered and dried at an ambient temperature to constant mass (2nd crop).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to a process for purification of a material comprising 4- [1-(1,2,4-triazolyl)methyl]benzonitrile of the formula (IV), comprising contacting the material comprising the compound of the formula (IV) (IV) and at least the compound (IVa) (IVa) with an aqueous acid, precipitation the solid state compound (IV) from the aqueous solution as a free base, and to the use of the purified compound of formula (IV) in preparing letrozole.

Description

PURIFICATION OF LETROZOLE INTERMEDIATE
[0001] Letrozole, 4,4'-(lH-l,2,4-triazol-l-ylmethylene)dibenzonitrile of the formula (I)
Figure imgf000002_0001
is a known compound used as a pharmaceutically active substance in the pharmaceutical industry.
Letrozole is indicated for, inter alia, treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. It is a non-steroidal competitive inhibitor of the aromatase enzyme system. Letrozole is marketed under the brand name FEMARA® by Novartis Pharmaceuticals as a film coated tablet containing 2.5 mg of letrozole as the free base.
[0002] US patent 4,978,672 (EP 236,940) describes the synthesis of letrozole by reacting 4-(bromomethyl)benzonitrile of the formula (II) and lH-l,2,4-triazole of the formula
(III) in a presence of a base to provide 4-[l-(l,2,4-triazolyl)methyl]benzonitrile of the formula (IV),
Figure imgf000002_0002
(H) (III) (IV) which is then purified by column chromatography and subsequently converted to letrozole of the formula (I) by the reaction with 4-fluorobenzonitrile of the formula (V) in a presence of a strong base.
Figure imgf000003_0001
(IV) (V) (I)
[0003] According to WO 2004/076409, the purification of the compound (IV) by column chromatography is necessary as the raw product is contaminated with approx. 20 to 40% of the side product of the reaction of (II) and (III), which is 4-[l-(l,3,4-triazolyl)methyl benzonitrile (IVa).
Figure imgf000003_0002
(IVa)
If not removed, this side product reacts with the compound (V) in the letrozole synthesis pathway to yield 4,4'-(lH-l,3,4-triazol-l-ylmethylene)bisbenzonitrile (Ia),
Figure imgf000003_0003
which is a site isomer of letrozole (and is called hereinunder as isoletrozole), the presence of which in the final product of pharmaceutical grade is undesirable. US Pharmacopoeia monograph restricts the maximum allowable amount of isoletrozole in the letrozole to max. 0.3 %.
[0004] The need of chromatographic purification makes the process economically unattractive.
[0005] WO 2004-076409 describes an alternative process avoiding the formation of the iso-compound (IVa), by using an amino-substituted triazole. However, this process requires an additional step of removing the amino-substituent, which may involve a formation of dangerous diazo-intermediates.
[0006] US 5,280,035 describes a process for making compound (IV) by converting 1 ,2,4-triazole into sodium salt ( by sodium hydride in DMF), followed by the reaction of this salt with (II). However, the compound (IV) must still be purified by column chromatography for to obtain the desired purity. In an improvement, US appl. 2005/0209294 isolates the compound (IV) by extraction/crystallization, however allowing for obtaining the product only with 96% purity.
[0007] WO 2007- 100346 improves the reaction between the 1 ,2,4-triazole salt and
(II) by using dimethylacetamide, N-methyl-2-pyrrolidone or combinations thereof as the solvent. In such a case, the compound (IV) needs not to be purified in some cases and the whole process leading to letrozole may be arranged in a one-pot process. Similar process is disclosed in WO 2007-039912.
[0008] WO 2007- 107733 discloses a process of making the compound (IV) employing the reaction of (II) and (III) in a presence of cesium carbonate. Under such process, the amounts of the formed undesired isomer (IVa) are lower.
[0009] It is apparent from the above that obtaining the compound (IV) in a proper quality is a key issue in any process of making letrozole by the above reaction sequence. The formation of the certain amount of the iso-product (IVa) may never be excluded, particularly in an industrial scale, and purification processes should be readily available. If a purification process is efficient and cheap, then the need to use extreme reaction conditions and expensive reagents may be avoided.
[0010] The process of purification of (IV) based on column chromatography disclosed above is not useful, particularly in an industrial scale due to its low capacity, time consumption and high cost.
[0011] WO 2005-047269 provides a crystallization process for purification of the mixtures of compounds (IV) and (IVa) comprising dissolving the isomeric mixture in dichloromethane, adding an isopropanolic solution of hydrogen chloride thereto, and adding isopropyl ether to the mixture to precipitate the undesired isomer ( i.e. the compound (IVa) ) in its hydrochloride form. The desired compound (IV) is then obtained from the filtrate by the precipitation as the hydrochloride salt and is then converted into a base.
[0012] WO 2007-100346 suggests a purification process based on an extraction involving an aqueous phase and water immiscible phase, which preferably contains C5-C12 hydrocarbon such as toluene, benzene and hexane. In a preferred arrangement comprising salted water as the aqueous phase and warmed toluene as the organic phase, the content of the iso-product (IVa) may be decreased to 1.5 %.This process is more effective than the extraction /crystallization process of US appl. 2005/0209294 shown above.
[0013] WO 2007-100346 also suggests that the raw intermediate (IV) may be further purified as its acid salt, e.g., the hydrochloride, hydrobromide or methane sulfonate. In the only disclosed example, the raw intermediate (IV) is dissolved in acetone, and the hydrochloride of (IV) is precipitated by adding concentrated aqueous HCl to this acetonic solution. The hydrochloride of the iso-product (IVa) remains in the solution.
[0014] WO 2007-054964 provides a purification of the reaction mixture comprising the (IV) and (IVa) compounds, comprising quenching the reaction mixture by water, adjusting the pH to acidic by slow addition of the sufficient amount of HCl, extracting of the acidic solution by a suitable organic solvent, e.g. a hydrocarbon, then basifying the organic phase to pH 7.5-10, saturating with NaCl and extracting again with the same solvent. The undesired regioisomer (IVa) remains in the aqueous phase.
[0015] While the above purification processes are available for making the compound (IV) essentially free from the compound (IVa), there is still a need of an improvement in the matter. In particular, purification processes, which do not employ organic solvents, are desirable from safety, economy and ecology aspects. BRIEF DESCRIPTION OF THE PRESENT INVENTION
[0016] The present invention is based on the discovery that 4-[l-(l,2,4- triazolyl)methyl]benzonitrile of the formula (IV) can be precipitated from an aqueous solution of an acid in a form of a free base and that such precipitation can dramatically increase the purity of the product. Furthermore, no organic solvent is used in the precipitation process.
[0017] Accordingly, a first aspect of the invention provides a process for purification of 4-[l-(l,2,4-triazolyl)methyl]benzonitrile of the formula (IV), comprising contacting the material comprising the compound (IV) and impurities, reaction side products and starting materials, such as the compound (IVa), with an aqueous acid, preferably hydrochloric acid, and precipitating the solid state compound (IV) from the mixture. This precipitation comprises preferably adjusting the pH to less acidic value.
[0018] The aqueous acid is preferably diluted hydrochloric acid , which preferably has a concentration of between 5 to 20 % ( w/v). [0019] In a particular aspect, 1 weight part of the material comprising the compound (IV) admixed with / impurified by the compound (IVa) is contacted with 2.5- 10 volume parts of the aqueous solution of the acid, preferably the hydrochloric acid.
[0020] In yet another particular aspect, the relative molar amount of the acid in respect to the molar amount of the compound (IV) is 1.5:1 to 2.5 :1.
[0021] In another particular aspect, the pH at the precipitation is adjusted to a value of at least 3.0 , preferably between 3.0 - 1 1.0, more preferably 6 - 10.
[0022] In a second aspect, the invention relates to a process for making a pharmaceutical grade letrozole of the formula (I) comprising the steps of
- providing a purified compound of the formula (IV) by the above process and
- reacting the purified compound (IV) with the compound (V) to form letrozole of the formula CD- DETAILED DESCRIPTION OF THE INVENTION
[0023] The present invention can purify the letrozole intermediate of the formula (IV) without the need to convert crude compound (IV) into an isolated acid addition salt thereof and/or to employ extraction steps using organic solvents. Instead, a simple process comprising precipitation of the compound (IV) as a free base from a solution thereof in a diluted aqueous acid may be employed, whereby the process allows to decrease not only the content of the iso- impurity of formula (IVa) but also other impurities arisen from the synthesis. As a result, a reagent grade compound of the formula (IV), i.e. a product having the content of the title compound of at least 99.7% and the content of any single structurally related impurity of less than 0.2 %, may be obtained in a simple and reliable process on an industrial scale. [0024] The purification process of the present invention is based on the finding that compounds (IV) and (IVa) have different solubility in the solvent comprising the diluted aqueous acid, particularly diluted aqueous hydrochloric acid , at different values of pH. If a mixture of compounds (IV) and (IVa), which typically arises from the synthesis comprising a condensation of the compound (II) and (III) and isolation of the reaction product from the reaction mixture, is dissolved in a diluted aqueous acid, particularly hydrochloric acid, and the pH of the mixture is adjusted to a less acidic value, typically to a pH higher than 3.0, the compound (IV) preferably precipitates from the solution as a free base, while the compound (IVa) stays dissolved in the solvent. The main advantage of the process is in that no organic solvent is employed therein, which has serious safety, economy and ecology impacts.
[0025] The first step of the purification process comprises contacting the crude compound (IV), i.e. the material comprising an admixture of the compound (IV) with the compound (IVa), herein referred to as the material , with a diluted aqueous acid. The crude material is typically obtained by a synthesis comprising a condensation of the compound (II) and (III), the conditions of which are well known in the art, eventually followed by pre- purification steps. In general, more than 0.5 %, sometimes even up to 5-10 %, of the iso- impurity (IVa) may be present in the material. The material may also comprise other impurities arising from the synthesis, particularly the unreacted 1,2,4-triazol and colour- forming impurities. The amount of the compound of formula (IV) in the starting material may be determined by routine analytical methods, e.g. by HPLC.
[0026] In particular, the amount of the acid in the diluted aqueous acid is usually from 0.1 to 3 molar equivalents, more typically 1.5 to 2.5 molar equivalents, in respect to the compound of formula (IV). In terms of concentration, the acid is normally less than 20%, preferably between 5 and 20%, based on the amount of water present. In terms of volume, the amount of the diluted aqueous acid is typically within the range of 2.5- 10 volume parts per 1 weight part of the crude material to be purified. The preferred acid is hydrochloric acid. However, it should be understood that hydrochloric acid is only an example of a suitable acid useful in the inventive process and the invention is by no way limited to using this acid only.
[0027] The mixture of the material and diluted aqueous acid is preferably heated to an enhanced temperature , preferably at a temperature of between 30 and 60 C and allowed to stir for certain time.
[0028] In a second optional step, the formed mixture is filtered to remove the solids and to form a clear filtrate. The solids are particularly represented by structurally related impurities present in the material. Advantageously, a small amount of a surface active material , such as activate carbon or kieselguhr is added prior to the filtration to the mixture , which not only enhances the speed of the filtration, but adsorbs also other impurities present in the starting material.
[0029] In a third step, the clear filtrate is treated with a base, preferably the inorganic base such as sodium or potassium hydroxide or carbonate, more preferably with an aqueous solution thereof , to adjust the pH of the solution to less acidic values. Typically, the pH is adjusted to a pH of 3.0 and more, more particularly to pH between 3.0 and 11.0, such as 6 - 10. At this pH range, the compound (IV) precipitates from the solution as a free base, not as a salt with the acid. The pH adjustment and precipitation is normally performed at ambient temperature. It is however possible to cool the reaction mixture before or after the pH adjustment to temperatures less than ambient, typically to 5- 15 °C. It is also possible to dilute the reaction mixture with another portion of water subsequently.
[0030] In the last step, the solid product is isolated from the mixture, typically by filtration or centrifugation, and optionally washed and dried. A second crop of the solid product may be obtained from the filtrate, particularly by salting the solution with NaCl and/or by further increasing the pH of the filtrate. [0031] The process may provide a product, i.e. the purified compound (IV), which generally comprises less than 0.2% , sometimes even less than 0.1 %, of the iso-impurity of the formula (IVa). If the desired limit is not reached, it is advantageous to repeat the purification process until the limit is reached. In average, no repetition is generally needed.
[0032] In general, the yield of the overall process, calculated on the amount of the starting material, is around 60 to 70%. The purification process does not require any extraction step and no organic solvent. It may be easily performed in multi-kilogram scale on single equipment.
[0033] The compound (IV) purified by the above process, particularly of the reagent grade specified above, is useful in a process for making letrozole. Accordingly, the above purification process steps may be followed by a subsequent step of converting the purified compound (IV) to letrozole, particularly by a condensation with the 4-fIuorobenzonitrile of the formula (V). The conditions of the condensation as well as of the isolation of letrozole from the reaction mixture are known in the art.
[0034] Because of a low content of the iso-compond of the formula (IVa) in the starting compound (IV), the letrozole may be produced with a low content of the isoletrozole of the formula (Ia), which is desirable from the pharmaceutical perspective. In particular, a pharmaceutical grade letrozole, i.e. a product having the content of the title compound of at least 99.7% and the content of any single structurally related impurity of less than 0.1 %, may be obtained in a simple and reliable process on an industrial scale.
[0035] The invention is further illustrated by the following examples.
Example 1
2 grams of the crude 4-[l-(l,2,4-triazolyl)methyl]benzonitrile , containing 0.5% of the compound of formula (IVa), was added to 10 ml of 12.5 % (w/v) aqueous HCl at ambient temperature and heated under stirring to 50°C. 0.1 g of activated charcoal was added and the mixture was stirred for 15 minutes. The mixture was filtered through a paper filter and washed with 5 ml of HCl (12.5 %) at 50°C. The filtrate was cooled to 10-15° C and 2M aqueous NaOH was added at this temperature until the pH 3.0. Crystalline suspension was allowed to stand overnight at 5-7 0C. The solid was filtered and dried at an ambient temperature to constant mass (1st crop).
The mother liquors were alkalinized by 2M aqueous NaOH at 10-15 °C to pH 8.0, 2 g of NaCl were added and the mixture was stirred at ambient temperature for 0.5 hours. Allowed to stand overnight at 5-7 °C. The solid was filtered and dried at an ambient temperature to constant mass ( 2nd crop).
Yield : 1.20 g ( 60.0 %) - 1st crop
0.33 g ( 16.5 % ) - 2nd crop
Content of the compound (IVa) (HPLC) : less than 0.05% Example 2
The experiment of the example 1 was repeated with the proviso that the pH of the first filtrate was adjusted by 2M Na OH to 6.0 .
Yield : 1.27 g ( 63.5 %) - 1st crop
0.14 g ( 7.0%) - 2nd crop
Content of the compound (IVa) (HPLC) : less than 0.05%
Example 3
3 grams of the crude 4-[l-(l,2,4-triazolyl)methyl]benzonitrile, containing 0.5% of the compound of formula (IVa), was mixed with 10 ml of 12.5 % (w/v) aqueous HCl at ambient temperature and heated under stirring at 50 °C. 0.1 g of activated charcoal was added and the mixture was stirred for 15 minutes at 50 °C. The mixture was filtered through a paper filter and washed with 3 ml of HCl (12.5 %) at 50 °C. The filtrate was cooled to 7-10 °C and 2M aqueous NaOH was added at 10-15 °C under stirring until the pH 10.0. Crystalline suspension was stirred at 7-10 °C for 1 hour. The solid was filtered and dried at an ambient temperature to constant mass (1 st crop).
The mother liquors were mixed with 2.2 g of NaCl and the mixture was stirred at ambient temperature for 0.5 hours. Allowed to stand overnight at 5-7 °C. The solid was filtered and dried at an ambient temperature to constant mass (2nd crop).
Yield : 2.41 g ( 80.3 %) of the 1st crop
0.11 g ( 3.7%) of the 2nd crop
Content of the compound (IVa) : less than 0.05 % ( HPLC)
The invention having been described it will be obvious that the same may be varied in many ways and all such modifications are contemplated as being within the scope of the invention as defined by the following claims.

Claims

CLAIMS 1. A process for purification of a material comprising 4-[ 1 -(I ,2,4- triazolyl)methyl]benzonitrile of the formula (IV), comprising
- contacting the material comprising the compound of the formula (IV)
Figure imgf000013_0001
and at least the compound (IVa)
Figure imgf000013_0002
with an aqueous acid,
- precipitation the solid state compound (IV) from the aqueous solution as a free base.
2. The process of claim 1, wherein the precipitation comprises adjusting the pH of the solution to a less acidic pH value, preferably to a less acidic pH value in the range of 3.0— 11.0.
3. The process of claim 2, wherein the pH is adjusted to a pH value in the range of 6— 10.
4. The process according to claims 1- 3, wherein the aqueous acid is the hydrochloric acid .
5. The process according to claims 1 - 4, wherein the aqueous acid has a concentration of between 5 to 20 % ( w/v) .
6. The process according to claims 1- 5 , wherein 1 weight part of the material is contacted with 2.5- 10 volume parts of the aqueous acid, preferably the hydrochloric acid.
7. The process according to claims 1-6 , wherein the relative molar amount of the acid, preferably the hydrochloric acid, is 1.5 : 1 to 2.5 : 1 in respect to the molar amount of the compound (IV)
8. The process according to claims 1-7, wherein the solution is filtered before precipitation, preferably in the presence of a surface active material .
9.The process according to claims 1—8, wherein the precipitated compound (IV) is isolated.
10. The process of claim 1 9, wherein the material originates form a reaction mixture of the reaction of 4-(bromomethyl)benzonitrile of the formula (II) and lH-l,2,4-triazole of the formula (III).
11. The process according to claims 1-10, further comprising the step of converting the isolated compound (IV) to letrozole .
12. A process for making a pharmaceutical grade letrozole of the formula (I)
Figure imgf000014_0001
comprising the steps of
- providing a purified compound of the formula (IV) by the process according to any of the claims 1-11 ; and
- reacting the purified compound (IV) with 4-fluorobenzonitrile of the formula (V) to form letrozole of the formula (I).
PCT/EP2009/004959 2009-07-02 2009-07-02 Purification of letrozole intermediate Ceased WO2011000396A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/004959 WO2011000396A1 (en) 2009-07-02 2009-07-02 Purification of letrozole intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/004959 WO2011000396A1 (en) 2009-07-02 2009-07-02 Purification of letrozole intermediate

Publications (1)

Publication Number Publication Date
WO2011000396A1 true WO2011000396A1 (en) 2011-01-06

Family

ID=40979385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/004959 Ceased WO2011000396A1 (en) 2009-07-02 2009-07-02 Purification of letrozole intermediate

Country Status (1)

Country Link
WO (1) WO2011000396A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012025762A3 (en) * 2010-08-27 2012-05-03 Generics [Uk] Limited Pure intermediate for preparing letrozole

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1754876A (en) * 2004-09-28 2006-04-05 北京德众万全医药科技有限公司 Process for preparing high purity letrozole
WO2007054964A2 (en) * 2005-10-20 2007-05-18 Cadila Healthcare Limited Process for the preparation of letrozole
WO2007100346A1 (en) * 2005-07-06 2007-09-07 Sicor, Inc. Improved process for the preparation of letrozole
WO2007134846A2 (en) * 2006-05-19 2007-11-29 Synthon B.V. Process for purification of anastrozole

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1754876A (en) * 2004-09-28 2006-04-05 北京德众万全医药科技有限公司 Process for preparing high purity letrozole
WO2007100346A1 (en) * 2005-07-06 2007-09-07 Sicor, Inc. Improved process for the preparation of letrozole
WO2007054964A2 (en) * 2005-10-20 2007-05-18 Cadila Healthcare Limited Process for the preparation of letrozole
WO2007134846A2 (en) * 2006-05-19 2007-11-29 Synthon B.V. Process for purification of anastrozole

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012025762A3 (en) * 2010-08-27 2012-05-03 Generics [Uk] Limited Pure intermediate for preparing letrozole
CN103298795A (en) * 2010-08-27 2013-09-11 基因里克斯(英国)有限公司 Pure intermediate for preparing letrozole
US9150524B2 (en) 2010-08-27 2015-10-06 Generics [Uk] Limited Pure intermediate

Similar Documents

Publication Publication Date Title
US7655806B2 (en) Process for purification of anastrozole
US8501935B2 (en) Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto
US20080214817A1 (en) Process for preparing n-alkylnaltrexone halides
JP2008516005A (en) Improved preparation of letrozole
WO2011021218A2 (en) Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
WO2008034644A2 (en) Process for making anastrozole
WO2007088558A2 (en) A process for purification of valsartan
BG107478A (en) Process for the crystallization of losartan potassium
US20130310571A1 (en) Methods for the preparation of bendamustine
EP1274702A1 (en) Process for the synthesis of a known tetrazol derivative
WO2011000396A1 (en) Purification of letrozole intermediate
US20090253746A1 (en) Synthesis and Preparations of Intermediates and New Polymorphs Thereof Useful For The Preparation Of Donepezil Hydrochlcoride
EP2167477B1 (en) Process for preparing pure valsartan
EP1896429A2 (en) A purification process for anastrozole intermediate
EP2016073B1 (en) Process for the preparation of pure irbesartan
KR100809159B1 (en) Improved Manufacturing Method of Rosatan
WO2011000395A1 (en) Purification of letrozole
WO2010029457A2 (en) An improved process for preparing losartan potassium
CA2433720A1 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
JP6275596B2 (en) Method for producing ammonium salt of telmisartan
EP1363882A1 (en) 3-(3-amidinophenyl)-5- ( 1-(1-(-iminoethyl)-4-piperidyl amino)methyl]benzoic acid dihydrochloride and process for preparing the same
WO2009010991A2 (en) Purification process to prepare highly pure anastrozole
WO2007020659A2 (en) A process for the preparation of irbesartan form a
JP2010077070A (en) Method for purifying imidazole derivative
WO2014206484A1 (en) Process for making anagrelide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09777055

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09777055

Country of ref document: EP

Kind code of ref document: A1